CLEVELAND--(BUSINESS WIRE)--Medical device and technology company Lazurite has received recognition from Medical Device Network Excellence Awards & Rankings, one of the largest, most prestigious, and widely recognized programs in the industry. Lazurite ranked as Commended for the Innovation, Product Launches and Research and Development categories. All Commended companies will be entered into the Medical Device Network Awards at the end of the year.
“The company is ranked off the back of the launch of its ArthroFree Wireless Surgical Camera System, which allows for minimally invasive surgery without the need for camera and light wires,” according to Medical Device Network Excellence Awards & Rankings. “The company hit an important milestone in March 2022 when it received U.S. Food and Drug Administration market clearance for the ArthroFree System. This was followed in September 2022 by another important step as the first surgery using the system was performed by orthopedic surgeon Laith M. Jazrawi, MD at NYU Langone Health.”
The statement continued, “The company had already made steps towards a market introduction in 2021, partnering with the Center for Health Affairs, the Northeast Ohio hospitals association, and its affiliate CHAMPS Group Purchasing, with an aim to provide new surgical tools in the market and operating rooms in Northeast Ohio and the U.S. This was followed by additional partnerships with Hospital for Special Surgery (HSS) in New York, University Hospitals of Cleveland, and LG Electronics USA.”
“We are proud to be recognized by Medical Device Network for innovation, product launches, and research and development in 2022,” Lazurite CEO and cofounder Eugene Malinskiy said. “The Medical Device Network platform is well known as a voice of authority in the global industry. This recognition will help us as we continue our launch of the ArthroFree System during the next several months and gain traction with our initial target market of orthopedic and sports medicine surgeons.”
About the Excellence Awards & Rankings
The Medical Device Network Excellence Awards & Rankings is an independent recognition program powered by the business intelligence of GlobalData. The program is a valuable part of GlobalData’s Medical Device Network platform. GlobalData’s team of researchers and journalists, along with artificial intelligence, analyzed 1 billion datasets during the year to recognize, endorse, and rank top-tier companies and their achievements in 200+ counties. The objective is to recognize forward-thinking, innovative companies that drive positive change in the industry. For more information see Medical Device Network and GlobalData.
Lazurite designs medtech devices, and its ArthroFree™ System is the first wireless camera with FDA clearance for arthroscopy and general endoscopy. It eliminates the camera cables associated with patient burns and fires, and it is drop-in compatible with current OR technologies. The ArthroFree wireless camera also allows untethered movement by surgeons, and projects cost-per-case savings of 20%. Lazurite’s IP portfolio also includes the high-efficiency, laser-driven Meridiem™ light technology, wireless communication technology, and products in development. Lazurite is located in Cleveland, OH (est. 2015), and has raised more than $25M from institutional investors, family offices, and more than 70 physician champions. The ten-year vision: better outcomes for one million patients—and thousands of clinicians, too. For more information, see https://lazurite.co.
This press release includes “forward-looking statements.” Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “expect,” “may,” “should,” “will,” “designed,” “promises,” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the expected impact of the ArthroFree System on the field of minimally invasive surgery and our future sales of the ArthroFree System. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Lazurite™, ArthroFree™, and Meridiem™ are trademarks of Lazurite Holdings LLC.
Visit lazurite.co/media for videos, logos, images, fact sheets, bios,